article Open AccessTop 1% cited
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
Clinical Pharmacology & Therapeutics · 2014 · Vol. 95(4) · pp. 376–382
Kristine R. Crews✉(St. Jude Children's Research Hospital)Andrea Gaedigk(University of Missouri–Kansas City)Henry M. Dunnenberger(St. Jude Children's Research Hospital)J. Steven Leeder(University of Missouri–Kansas City)Teri E. Klein(Stanford University)Kelly E. Caudle(St. Jude Children's Research Hospital)Cyrine E. Haidar(St. Jude Children's Research Hospital)Danny D. Shen(University of Washington)John T. Callaghan(Indiana University – Purdue University Indianapolis)Senthilkumar Sadhasivam(Cincinnati Children's Hospital Medical Center)Cynthia A. Prows(Cincinnati Children's Hospital Medical Center)E D Kharasch(Washington University in St. Louis)Todd C. Skaar(Indiana University – Purdue University Indianapolis)
Abstract
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.
Pharmacogenetics and Drug MetabolismCancer Treatment and PharmacologyPain Management and Opioid UseCodeineCYP2D6PharmacogeneticsMedicineGenotypePharmacologyOpioidMorphineCytochrome P450Internal medicine
MeSH terms
Analgesics, OpioidCodeineGenetic TestingGenotypeHumansMorphinePharmacogeneticsPolymorphism, GeneticCytochrome P-450 CYP2D6
Funding
- American Lebanese Syrian Associated Charities
- National Institutes of Health
- Agency for Healthcare Research and Quality
Citations
673
FWCI
86.03
field-weighted impact
References
43
Percentile
100%
vs. same field & year
Citations per year
Cited by
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and <i>CYP2C19</i> Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Clinical Pharmacology & Therapeutics · 2015 · 958 citations
References
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Clinical Pharmacology & Therapeutics · 2007 · 784 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.